This site does not provide specific medical advice and does not endorse
any medical or professional service obtained through information provided
on this site or any links to this site. Please check with a physician or
health professional if you suspect you are ill.
The European Agency on Medicines Agency (EMA) has, in fact, a positive opinion for use of a drug for people with lung cancer made on the basis of a study conducted by Federico Cappuzzo, director of 'operative Oncology Company USL 6 of Livorno.
The drug in question is called Tarceva and significantly delay tumor growth, increasing life and improving symptoms such as cough and pain associated with the disease.
This flourish as well as being a very important step towards the treatment of cancer is also a source of satisfaction for repaorto livlornese cancer, so that is at the forefront in treating lung cancer, the more 'common with one million and 500 thousand new cases each year worldwide.
Cappuzzo said that the particular tumor defined as non-small cell carcinoma, when in metastatic progresses rapidly and allows a median survival of approximately one year.
The use of this drug, after chemotherapy, significantly delaying the spread allowing to improve the appearance and quality of life.
The study, conducted worldwide and led by Dr. Cappuzzo, involving almost a thousand patients showed a 41% reduction in the risk of progression and 23% risk of death.
Data, therefore, very encouraging for this oral therapy that is placed as the first oral maintenance can also continue to aggressively treat the disease after initial chemotherapy without the need for additional care.
